WebNov 14, 2016 · PRINCETON, N.J. and LUND, Sweden, Nov. 14, 2016 /PRNewswire/ -- America's opioid crisis is taking the life of a person every 19 minutes. Responding to this crisis, Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) are pleased to announce positive top-line results from a pivotal Phase 3 randomized, double-blind, … WebApr 11, 2024 · Position Summary: The Key Account Manager will help Braeburn accomplish its purpose by educating Healthcare Professionals (HCPs) about Braeburn's products and related access resources. This role will help to ensure HCPs are fully informed about the clinical aspects of the product as well as how to obtain the product when making an …
FDA slaps down Braeburn on opioid addiction drug, putting …
Web03/31/2024 - Sales. Remote Worker - N/A. Facilities/Maintenance Mechanics. 03/30/2024 - Facilities. 2033B Brunswick Business Park. Analyst/Intern, Commercial Insights and Analytics. 03/30/2024 - Commercial. 2031B Brunswick Business Park. Packaging Technician Lead - 2nd Shift. WebOur benefit programs currently include: Comprehensive medical and dental programs (Transparency in Coverage) 401 (k) retirement plan Flexible spending accounts (medical and dependent care) Health reimbursement account Health savings account Vision insurance Voluntary benefits, including programs such as pet insurance and income … fort benning school for boys
Teaching careers at Braeburn - Braeburn Schools
WebDec 10, 2024 · Careers; Our Disease Area. Opioid Use Disorder; Patient Journey; Research & Development. Pipeline; Publications & Conference Abstracts; Grants; Investors & Media. Investors; ... Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO read more. May 02 2024 Braeburn and Camurus Announce Positive Top-line Results from … WebJun 5, 2024 · PRINCETON, N.J., June 5, 2024 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. WebMay 17, 2024 · With an ongoing Phase III efficacy study due to complete later this year and an aim for New Drug Application (NDA) filing by the end of 2024, Braeburn Pharmaceuticals remains on the heels of competitor companies developing other long-acting risperidone treatments for schizophrenia patients. fort benning school calendar 2021-22